BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Nov 1

PMID 22039425

Citations 40

Authors

Hazem El-Osta

Gerald Falchook

Apostolia Tsimberidou

David Hong

Aung Naing

Kevin Kim

Sijin Wen

Filip Janku

Razelle Kurzrock

Affiliations

Soon will be listed here.

Abstract

Background: Oncogenic BRAF mutations have been found in diverse malignancies and activate RAF/MEK/ERK signaling, a critical pathway of tumorigenesis. We examined the clinical characteristics and outcomes of patients with mutant (mut) BRAF advanced cancer referred to phase 1 clinic.

Methods: We reviewed the records of 80 consecutive patients with mutBRAF advanced malignancies and 149 with wild-type (wt) BRAF (matched by tumor type) referred to the Clinical Center for Targeted Therapy and analyzed their outcome.

Results: Of 80 patients with mutBRAF advanced cancer, 56 had melanoma, 10 colorectal, 11 papillary thyroid, 2 ovarian and 1 esophageal cancer. Mutations in codon 600 were found in 77 patients (62, V600E; 13, V600K; 1, V600R; 1, unreported). Multivariate analysis showed less soft tissue (Odds ratio (OR) = 0.39, 95%CI: 0.20-0.77, P = 0.007), lung (OR = 0.38, 95%CI: 0.19-0.73, p = 0.004) and retroperitoneal metastases (OR = 0.34, 95%CI: 0.13-0.86, p = 0.024) and more brain metastases (OR = 2.05, 95%CI: 1.02-4.11, P = 0.043) in patients with mutBRAF versus wtBRAF. Comparing to the corresponding wtBRAF, mutBRAF melanoma patients had insignificant trend to longer median survival from diagnosis (131 vs. 78 months, p = 0.14), while mutBRAF colorectal cancer patients had an insignificant trend to shorter median survival from diagnosis (48 vs. 53 months, p = 0.22). In melanoma, V600K mutations in comparison to other BRAF mutations were associated with more frequent brain (75% vs. 36.3%, p = 0.02) and lung metastases (91.6% vs. 47.7%, p = 0.007), and shorter time from diagnosis to metastasis and to death (19 vs. 53 months, p = 0.046 and 78 vs. 322 months, p = 0.024 respectively). Treatment with RAF/MEK targeting agents (Hazard ratio (HR) = 0.16, 95%CI: 0.03-0.89, p = 0.037) and any decrease in tumor size after referral (HR = 0.07, 95%CI: 0.015-0.35, p = 0.001) correlated with longer survival in mutBRAF patients.

Conclusions: BRAF appears to be a druggable mutation that also defines subgroups of patients with phenotypic overlap, albeit with differences that correlate with histology or site of mutation.

Citing Articles

Molecular Underpinnings of Brain Metastases.

Jacome M, Wu Q, Chen J, Mohamed Z, Mokhtari S, Pina Y Int J Mol Sci. 2025; 26(5).

PMID: 40076927 PMC: 11900073. DOI: 10.3390/ijms26052307.

An Optimized CRISPR/Cas12a Assay to Facilitate the BRAF V600E Mutation Detection.

Etemadzadeh A, Salehipour P, Motlagh F, Khalifeh M, Asadbeigi A, Tabrizi M J Clin Lab Anal. 2024; 38(21):e25101.

PMID: 39445676 PMC: 11555610. DOI: 10.1002/jcla.25101.

Prognostic Value of Baseline F-FDG PET/CT to Predict Brain Metastasis Development in Melanoma Patients.

Kalantari F, Mirshahvalad S, Hoellwerth M, Schweighofer-Zwink G, Huber-Schonauer U, Hitzl W Cancers (Basel). 2024; 16(1).

PMID: 38201554 PMC: 10778001. DOI: 10.3390/cancers16010127.

Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.

Gurav M, Epari S, Gogte P, Pai T, Deshpande G, Karnik N J Cancer Res Clin Oncol. 2023; 149(10):7413-7425.

PMID: 36935431 DOI: 10.1007/s00432-023-04693-3.

Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases.

Wilcox J, Boire A CNS Drugs. 2022; 37(1):45-67.

PMID: 36474108 PMC: 9829628. DOI: 10.1007/s40263-022-00975-5.

References

Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H . BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer. 2010; 102(12):1762-8. PMC: 2883698. DOI: 10.1038/sj.bjc.6605694. View

Eberhard D, Johnson B, Amler L, Goddard A, Heldens S, Herbst R . Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005; 23(25):5900-9. DOI: 10.1200/JCO.2005.02.857. View

Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S . BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res. 2003; 9(9):3362-8. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Balch C, Soong S, Gershenwald J, Thompson J, Reintgen D, Cascinelli N . Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19(16):3622-34. DOI: 10.1200/JCO.2001.19.16.3622. View

Curtin J, Fridlyand J, Kageshita T, Patel H, Busam K, Kutzner H . Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005; 353(20):2135-47. DOI: 10.1056/NEJMoa050092. View

Richman S, Seymour M, Chambers P, Elliott F, Daly C, Meade A . KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27(35):5931-7. DOI: 10.1200/JCO.2009.22.4295. View

10.

Tol J, Nagtegaal I, Punt C . BRAF mutation in metastatic colorectal cancer. N Engl J Med. 2009; 361(1):98-9. DOI: 10.1056/NEJMc0904160. View

11.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A . Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer. 2006; 13(2):455-64. DOI: 10.1677/erc.1.01086. View

12.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G . Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11(8):753-62. DOI: 10.1016/S1470-2045(10)70130-3. View

13.

Shinozaki M, Fujimoto A, Morton D, Hoon D . Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004; 10(5):1753-7. DOI: 10.1158/1078-0432.ccr-1169-3. View

14.

Curtin J, Busam K, Pinkel D, Bastian B . Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24(26):4340-6. DOI: 10.1200/JCO.2006.06.2984. View

15.

Zuo Z, Chen S, Chandra P, Galbincea J, Soape M, Doan S . Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol. 2009; 22(8):1023-31. DOI: 10.1038/modpathol.2009.59. View

16.

Chang D, Panageas K, Osman I, Polsky D, Busam K, Chapman P . Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med. 2004; 2(1):46. PMC: 544849. DOI: 10.1186/1479-5876-2-46. View

17.

Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner G, Zepf D . PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10(6):534-41. PMC: 2386538. DOI: 10.1593/neo.08336. View

18.

Sakr R, Barbashina V, Morrogh M, Chandarlapaty S, Andrade V, Arroyo C . Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol. 2010; 18(4):371-4. PMC: 2921801. DOI: 10.1097/PAI.0b013e3181d50bd5. View

19.

Flaherty K, McArthur G . BRAF, a target in melanoma: implications for solid tumor drug development. Cancer. 2010; 116(21):4902-13. DOI: 10.1002/cncr.25261. View

20.

Xing M, Westra W, Tufano R, Cohen Y, Rosenbaum E, Rhoden K . BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005; 90(12):6373-9. DOI: 10.1210/jc.2005-0987. View